Unknown

Dataset Information

0

C-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.


ABSTRACT: Strategies to inhibit the EGF receptor (EGFR) using the tyrosine kinase inhibitor erlotinib have been associated with limited clinical efficacy in head and neck squamous cell carcinoma (HNSCC). Co-activation of alternative kinases may contribute to erlotinib resistance.We generated HNSCC cells expressing dominant-active c-Src (DA-Src) to determine the contribution of c-Src activation to erlotinib response.Expression of DA-Src conferred resistance to erlotinib in vitro and in vivo compared with vector-transfected control cells. Phospho-Met was strongly upregulated by DA-Src, and DA-Src cells did not produce hepatocyte growth factor (HGF). Knockdown of c-Met enhanced sensitivity to erlotinib in DA-Src cells in vitro, as did combining a c-Met or c-Src inhibitor with erlotinib. Inhibiting EGFR resulted in minimal reduction of phospho-Met in DA-Src cells, whereas complete phospho-Met inhibition was achieved by inhibiting c-Src. A c-Met inhibitor significantly sensitized DA-Src tumors to erlotinib in vivo, resulting in reduced Ki67 labeling and increased apoptosis. In parental cells, knockdown of endogenous c-Src enhanced sensitivity to erlotinib, whereas treatment with HGF to directly induce phospho-Met resulted in erlotinib resistance. The level of endogenous phospho-c-Src in HNSCC cell lines was also significantly correlated with erlotinib resistance.Ligand-independent activation of c-Met contributes specifically to erlotinib resistance, not cetuximab resistance, in HNSCC with activated c-Src, where c-Met activation is more dependent on c-Src than on EGFR, providing an alternate survival pathway. Addition of a c-Met or c-Src inhibitor to erlotinib may increase efficacy of EGFR inhibition in patients with activated c-Src.

SUBMITTER: Stabile LP 

PROVIDER: S-EPMC3549019 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.

Stabile Laura P LP   He Guoqing G   Lui Vivian Wai Yan VW   Thomas Sufi S   Henry Cassandra C   Gubish Christopher T CT   Joyce Sonali S   Quesnelle Kelly M KM   Siegfried Jill M JM   Grandis Jennifer R JR  

Clinical cancer research : an official journal of the American Association for Cancer Research 20121204 2


<h4>Purpose</h4>Strategies to inhibit the EGF receptor (EGFR) using the tyrosine kinase inhibitor erlotinib have been associated with limited clinical efficacy in head and neck squamous cell carcinoma (HNSCC). Co-activation of alternative kinases may contribute to erlotinib resistance.<h4>Experimental design</h4>We generated HNSCC cells expressing dominant-active c-Src (DA-Src) to determine the contribution of c-Src activation to erlotinib response.<h4>Results</h4>Expression of DA-Src conferred  ...[more]

Similar Datasets

| S-EPMC3460647 | biostudies-literature
2013-08-10 | E-GEOD-49135 | biostudies-arrayexpress
| S-EPMC6554031 | biostudies-literature
2013-08-10 | GSE49135 | GEO
| S-EPMC3225383 | biostudies-literature
| S-EPMC3875956 | biostudies-literature
| S-EPMC5342798 | biostudies-literature
| S-EPMC4209288 | biostudies-literature
| S-EPMC5742817 | biostudies-literature
2019-12-18 | PXD007785 | Pride